drugset / Trial / NCT07077512
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Phase 2
Recruiting
30 enrolled
Sun Yat-sen University
Fifth Affiliated Hospital of Guangzhou Medical University · collabGuangzhou Overseas Chinese Hospital,Guangdong · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Timeline
- Start
- 2025-09-15
- Primary completion
- 2027-01-15
- Completion
- 2027-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relmacabtagene Autoleucel | Cell therapy | — | Other |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |